Pacific Biosciences
PACB
#7723
Rank
S$0.56 B
Marketcap
S$1.81
Share price
2.94%
Change (1 day)
-2.53%
Change (1 year)

P/E ratio for Pacific Biosciences (PACB)

P/E ratio as of July 2026 (TTM): -3.26

According to Pacific Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.25581. At the end of 2025 the company had a P/E ratio of -1.02.

P/E ratio history for Pacific Biosciences from 2011 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025-1.02-36.69%
2024-1.61-80.2%
2023-8.1138.76%
2022-5.84-74.58%
2021-23.0-110.63%
2020216-2415.57%
2019-9.34-2.86%
2018-9.61223.99%
2017-2.97
2015-30.5266.11%
2014-8.34102.53%
2013-4.12311.81%
2012-1.00

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Thermo Fisher Scientific
TMO
28.7-982.42%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
39.8-1,322.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Illumina
ILMN
34.8-1,169.34%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-559.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Luminex
LMNX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
NanoString Technologies
NSTG
-0.0298-99.08%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.